Form 8-K - Current report:
SEC Accession No. 0001539497-24-000541
Filing Date
2024-02-21
Accepted
2024-02-21 16:07:56
Documents
14
Period of Report
2024-02-20
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K n3936_x4-8k.htm   iXBRL 8-K 43965
  Complete submission text file 0001539497-24-000541.txt   219606

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE blcm-20240220.xsd EX-101.SCH 3015
3 XBRL LABEL FILE blcm-20240220_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE blcm-20240220_pre.xml EX-101.PRE 22359
15 EXTRACTED XBRL INSTANCE DOCUMENT n3936_x4-8k_htm.xml XML 7493
Mailing Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098
Business Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Filer) CIK: 0001358403 (see all company filings)

EIN.: 201450200 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36783 | Film No.: 24659448
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)